Velocity Clinical Research, the leading multi-specialty clinical sites business, today announces the appointment of Rachael Buck Ph.D. as Country Head in the U.K. Rachael will lead the five sites Velocity currently owns and operates in the U.K. and will work with the rest of Velocity’s European executive team to expand the company’s footprint in the … Read more
Velocity sites and investigators have supported research for nine products that have received U.S. FDA approval in 2024. These include, but are not limited to: Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), the first FDA-approved #MASH drug. Moderna’s mRESVIA, an mRNA RSV vaccine for adults 60 and older. Eli Lilly and Company’s Kisunla (donanemab) for patients with early … Read more
Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, today announces it has appointed Mike Zaranek as Chief Financial Officer (CFO). Reporting to Velocity President and CEO Paul Evans with immediate effect, Zaranek will direct the company’s financial goals and accounting, and advise on the Company’s strategic direction. Mike brings nearly three decades of … Read more
Velocity has now paid more than $1.1 million in patient study stipends through our VISION Engage app. Here’s why this matters: Patients get: Prompt, secure in-app payments Direct bank transfers or virtual debit card options Enhanced visibility and flexibility Sites get: Seamless integration with existing workflows Reduced administrative burden Improved patient satisfaction and retention Explore … Read more
Raghu Punnamraju, Chief Technology Officer at Velocity, was recently interviewed by CIO News about applying a lean-value approach to our technical product management, engineering, and architectural strategies. Through the development of our VISION platform, and new frameworks that leverage LLMs, this article details how Raghu and our team in Hyderabad, India, are continuously delivering solutions … Read more
The Velocity team had the honor of hosting former U.S. Surgeon General and Chairman of the Board of TOTAL Diversity Clinical Trial Management, Jerome Adams, MD, MPH. He joined an internal call to discuss the importance of diversity in clinical research, highlighting the need for diverse patient populations in clinical trials to ensure new treatments … Read more
Velocity has announced a new site in St. Louis, its first in Missouri. The site will be co-located with West County Rheumatology, one of the largest and most active infusion centers in the Midwest, and a region-leading clinic for patients with rheumatoid arthritis, psoriatic arthritis, lupus, fibromyalgia, and hypermobility disorders. An elected Fellow of the … Read more
The narrative that’s been peddled for the past three decades has seen obesity become mired in controversy, leading many – even healthcare professionals – to view it as a lifestyle choice rather than a disease. Nearly 40% of the global population has a body mass index (BMI) higher than 25 kg/m2, meaning they’re overweight or … Read more
Paul Evans, Velocity President and CEO, was featured in a Triangle Business Journal article covering Velocity’s recent partnership announcement with Luminis Health. As Paul notes in the article, hospitals play a crucial role in clinical research due to their patient populations, particularly in specialized fields like oncology. Velocity will take over the operation of the hospital’s … Read more
Kris Kowdley, MD, contributed significantly to the clinical research program that led to accelerated FDA approval of Ipsen’s Iqirvo, a first-in-class treatment for primary biliary cholangitis (PBC), a rare liver disease. As a primary investigator for the Phase 3 ELATIVE trial, Dr. Kowdley’s site enrolled the first patient in the study, and he was the … Read more